FDA Cracks Down On Cheap, Effective “CCP Virus” Drug Interventions

On May 20, the U.S. Food and Drug Administration (FDA) denied emergency use authorization for fluvoxamine to interfere with the CCP virus. Fluvoxamine, a selective 5-hydroxytryptamine reuptake inhibitor used clinically for the treatment of OCD and depression, is an inexpensive and widely available generic drug. The study showed that fluvoxamine may improve oxygen saturation, reduce oxygenation, and reduce the risk of hospitalization in outpatients infected with the CCP virus. As of May 21, 2022, four studies from four independent teams in three different countries have shown statistically significant improvements in CCP virus interventions worldwide.

However, on April 29, 2022, the FDA denied an emergency authorization application for fluvoxamine submitted by the University of Minnesota, citing “insufficient data, uncertainty about the drug’s mechanism of action, and that patients already had Pfizer’s antiviral drug Paxlovid.” Professor Boulware of the University of Minnesota, who was involved in the clinical study of fluvoxamine, objected to the FDA’s decision. He argues that regulatory agencies, such as the FDA, are picky about positive and credible clinical data for inexpensive and effective drugs, but give special favor to Merck’s molnupiravir, which is subject to controversy over its safety and efficacy but granted authorization for the emergency use.

It is no coincidence that since the outbreak of the CCP virus, pharmaceutical regulators in various countries, in collaboration with “big pharma,” have promoted poor quality experimental vaccines, deliberately suppressing inexpensive and effective interventions, such as ivermectin and hydroxychloroquine, regardless of the vaccines’ limited antiviral efficacy and serious adverse reactions. In the post-epidemic era, more and more clinical practitioners and experts are becoming aware of this global scandal.